{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:01:31Z","timestamp":1790683291983,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.phrs.2022.106631","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T12:17:01Z","timestamp":1672229821000},"page":"106631","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Role of monomeric amyloid-\u03b2 in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies"],"prefix":"10.1016","volume":"187","author":[{"given":"Bruno P.","family":"Imbimbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Ippati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Watling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Imbimbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.phrs.2022.106631_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/JAD-180321","article-title":"Plasma A\u03b242 as a biomarker of prodromal alzheimer's disease progression in patients with amnestic mild cognitive impairment: evidence from the PharmaCog\/E-ADNI study","volume":"69","author":"Albani","year":"2019","journal-title":"J. Alzheimers Dis."},{"issue":"6","key":"10.1016\/j.phrs.2022.106631_bib2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archneur.56.6.673","article-title":"Cerebrospinal fluid \u03b2-amyloid42 in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease","volume":"56","author":"Andreasen","year":"1999","journal-title":"Arch. Neurol."},{"issue":"3 Pt 1","key":"10.1016\/j.phrs.2022.106631_bib3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/WNL.42.3.631","article-title":"Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease","volume":"42","author":"Arriagada","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2022.106631_bib4","first-page":"106","article-title":"Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer\u2019s disease treated with bapineuzumab: a historical, prospective secondary analysis","volume":"87","author":"Arrighi","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.phrs.2022.106631_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/85525","article-title":"Imaging of amyloid-\u03b2 deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy","volume":"7","author":"Bacskai","year":"2001","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.phrs.2022.106631_bib6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.21623","article-title":"A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system","volume":"66","author":"Bateman","year":"2009","journal-title":"Ann. Neurol."},{"issue":"12","key":"10.1016\/j.phrs.2022.106631_bib7","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","article-title":"Neuropathology of older persons without cognitive impairment from two community-based studies","volume":"66","author":"Bennett","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2022.106631_bib8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fnagi.2018.00118","article-title":"The physiological roles of amyloid-\u03b2 peptide hint at new ways to treat Alzheimer's disease","volume":"10","author":"Brothers","year":"2018","journal-title":"Front. Aging Neurosci."},{"issue":"2","key":"10.1016\/j.phrs.2022.106631_bib9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"10","key":"10.1016\/j.phrs.2022.106631_bib10","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1474-4422(16)30125-9","article-title":"Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study","volume":"15","author":"Burnham","year":"2016","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106631_bib11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3233\/JAD-2009-1151","article-title":"Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta","volume":"18","author":"Castellani","year":"2009","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.phrs.2022.106631_bib12","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.arr.2012.06.007","article-title":"Rational heterodoxy: cholesterol reformation of the amyloid doctrine","volume":"12","author":"Castello","year":"2013","journal-title":"Ageing Res. Rev."},{"issue":"9","key":"10.1016\/j.phrs.2022.106631_bib13","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid beta: structure, biology and structure-based therapeutic development","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.phrs.2022.106631_bib14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.nicl.2013.02.006","article-title":"Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease","volume":"2","author":"Ch\u00e9telat","year":"2013","journal-title":"Neuroimage Clin."},{"issue":"22","key":"10.1016\/j.phrs.2022.106631_bib15","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1001\/jama.2017.6669","article-title":"Alzheimer\u2019s disease neuroimaging initiative. association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons","volume":"317","author":"Donohue","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.phrs.2022.106631_bib16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2022.106631_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2022.106631_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13195-015-0121-6","article-title":"Peripheral and central effects of \u03b3-secretase inhibition by semagacestat in Alzheimer's disease","volume":"7","author":"Doody","year":"2015","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.phrs.2022.106631_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109002","article-title":"Exogenous A\u03b242 monomers improve synaptic and cognitive function in Alzheimer's disease model mice","volume":"209","author":"Duan","year":"2022","journal-title":"Neuropharmacology"},{"issue":"18","key":"10.1016\/j.phrs.2022.106631_bib20","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease","volume":"378","author":"Egan","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.phrs.2022.106631_bib21","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer's disease","volume":"380","author":"Egan","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2022.106631_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13195-019-0520-1","article-title":"Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease","volume":"11","author":"Egan","year":"2019","journal-title":"Alzheimers Res. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2022.106631_bib23","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3233\/JAD-210415","article-title":"Soluble amyloid-\u03b2 consumption in Alzheimer's disease","volume":"82","author":"Espay","year":"2021","journal-title":"J. Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.phrs.2022.106631_bib24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/biology11040535","article-title":"Proteins do not replicate, they precipitate: phase transition and loss of function toxicity in amyloid pathologies","volume":"11","author":"Ezzat","year":"2022","journal-title":"Biology"},{"issue":"2","key":"10.1016\/j.phrs.2022.106631_bib25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ana.21559","article-title":"Decreased cerebrospinal fluid A\u03b242 correlates with brain atrophy in cognitively normal elderly","volume":"65","author":"Fagan","year":"2009","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106631_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/187152710791012017","article-title":"Amyloid-\u03b2 immunotherapy for Alzheimer's disease","volume":"9","author":"Fu","year":"2010","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"9","key":"10.1016\/j.phrs.2022.106631_bib27","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/01.WNL.0000063311.58879.01","article-title":"Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease","volume":"60","author":"Giannakopoulos","year":"2003","journal-title":"Neurology"},{"issue":"34","key":"10.1016\/j.phrs.2022.106631_bib28","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1523\/JNEUROSCI.1736-09.2009","article-title":"\u03b2-amyloid monomers are neuroprotective","volume":"29","author":"Giuffrida","year":"2009","journal-title":"J. Neurosci."},{"issue":"8","key":"10.1016\/j.phrs.2022.106631_bib29","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","article-title":"The \u03b2-secretase BACE1 in Alzheimer's disease","volume":"89","author":"Hampel","year":"2021","journal-title":"Biol. Psychiatry"},{"issue":"50","key":"10.1016\/j.phrs.2022.106631_bib30","doi-asserted-by":"crossref","first-page":"16755","DOI":"10.1523\/JNEUROSCI.4521-10.2010","article-title":"Reimagining Alzheimer's disease\u2013an age-based hypothesis","volume":"30","author":"Herrup","year":"2010","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.phrs.2022.106631_bib31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2022.106631_bib32","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002684","article-title":"Effects of heart bypass surgery on plasma A\u03b240 and A\u03b242 levels in infants and young children","volume":"95","author":"Hu","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.phrs.2022.106631_bib33","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/13543784.2019.1683160","article-title":"Investigational BACE inhibitors for the treatment of Alzheimer\u2019s disease","volume":"28","author":"Imbimbo","year":"2019","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"14","key":"10.1016\/j.phrs.2022.106631_bib34","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.3390\/ijms21144920","article-title":"The use of antimicrobial and antiviral drugs in Alzheimer's disease","volume":"21","author":"Iqbal","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.phrs.2022.106631_bib35","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.phrs.2022.106631_bib36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5607\/en22004","article-title":"Physiological roles of monomeric amyloid-\u03b2 and implications for Alzheimer's disease therapeutics","volume":"31","author":"Jeong","year":"2022","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.phrs.2022.106631_bib37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cortex.2017.09.018","article-title":"Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum","volume":"97","author":"Jones","year":"2017","journal-title":"Cortex"},{"issue":"8","key":"10.1016\/j.phrs.2022.106631_bib38","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1093\/brain\/awx148","article-title":"Slow wave sleep disruption increases cerebrospinal fluid amyloid-\u03b2 levels","volume":"140","author":"Ju","year":"2017","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.phrs.2022.106631_bib39","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2022.106631_bib40","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00401-020-02196-w","article-title":"The physiological roles of tau and A\u03b2: implications for Alzheimer's disease pathology and therapeutics","volume":"140","author":"Kent","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.phrs.2022.106631_bib41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pneurobio.2016.06.004","article-title":"Alzheimer's disease due to loss of function: a new synthesis of the available data","volume":"143","author":"Kepp","year":"2016","journal-title":"Prog. Neurobiol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106631_bib42","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jalz.2011.05.2429","article-title":"Is Alzheimer's disease amyloidosis the result of a repair mechanism gone astray?","volume":"8","author":"Kokjohn","year":"2012","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10.1016\/j.phrs.2022.106631_bib43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2012.236","article-title":"Deciphering the mechanism underlying late-onset Alzheimer disease","volume":"9","author":"Krstic","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.phrs.2022.106631_bib44","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.brainresbull.2016.11.008","article-title":"Platelets are responsible for the accumulation of \u03b2-amyloid in blood clots inside and around blood vessels in mouse brain after thrombosis","volume":"128","author":"Kucheryavykh","year":"2017","journal-title":"Brain Res. Bull."},{"issue":"50","key":"10.1016\/j.phrs.2022.106631_bib45","doi-asserted-by":"crossref","first-page":"11693","DOI":"10.1523\/JNEUROSCI.2766-05.2005","article-title":"BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions","volume":"25","author":"Laird","year":"2005","journal-title":"J. Neurosci."},{"issue":"12","key":"10.1016\/j.phrs.2022.106631_bib46","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jamainternmed.2021.6045","article-title":"FDA drug approval and the ethics of desperation","volume":"181","author":"Largent","year":"2021","journal-title":"JAMA Intern. Med."},{"issue":"6","key":"10.1016\/j.phrs.2022.106631_bib47","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41593-022-01084-8","article-title":"Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of A\u03b2 in neurons, yielding senile plaques","volume":"25","author":"Lee","year":"2022","journal-title":"Nat. Neurosci."},{"issue":"7","key":"10.1016\/j.phrs.2022.106631_bib48","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1212\/WNL.0000000000013211","article-title":"Validation of plasma amyloid-\u03b2 42\/40 for detecting Alzheimer disease amyloid plaques","volume":"98","author":"Li","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2022.106631_bib49","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-021-00557-x","article-title":"Can we learn lessons from the FDA's approval of aducanumab?","volume":"17","author":"Liu","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106631_bib50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ana.25117","article-title":"Effect of sleep on overnight cerebrospinal fluid amyloid \u03b2 kinetics","volume":"83","author":"Lucey","year":"2018","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106631_bib51","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3109\/02699052.2013.771797","article-title":"Beneficial effect of amyloid beta after controlled cortical impact","volume":"27","author":"Mannix","year":"2013","journal-title":"Brain Inj."},{"issue":"18","key":"10.1016\/j.phrs.2022.106631_bib52","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2022.106631_bib53","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3233\/JAD-2010-1230","article-title":"A physiological role for amyloid-beta protein: enhancement of learning and memory","volume":"19","author":"Morley","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2022.106631_bib54","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of crenezumab vs Placebo in adults with early Alzheimer disease: two phase 3 randomized Placebo-controlled trials","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106631_bib55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res. Ther."},{"issue":"29","key":"10.1016\/j.phrs.2022.106631_bib56","doi-asserted-by":"crossref","first-page":"6926","DOI":"10.1523\/JNEUROSCI.3607-16.2017","article-title":"Amyloid-\u03b2 peptide is needed for cGMP-induced long-term potentiation and memory","volume":"37","author":"Palmeri","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2022.106631_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2019.100948","article-title":"Do anti-amyloid-\u03b2 drugs affect neuropsychiatric status in Alzheimer's disease patients?","volume":"55","author":"Panza","year":"2019","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.phrs.2022.106631_bib58","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106631_bib59","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.25410","article-title":"Amyloid-\u03b2 immunotherapy for alzheimer disease: Is it now a long shot?","volume":"85","author":"Panza","year":"2019","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106631_bib60","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/jamaneurol.2015.3098","article-title":"Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community","volume":"73","author":"Petersen","year":"2016","journal-title":"JAMA Neurol."},{"issue":"Pt 11","key":"10.1016\/j.phrs.2022.106631_bib61","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1093\/brain\/awm238","article-title":"Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease","volume":"130","author":"Pike","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.phrs.2022.106631_bib62","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.phrs.2022.106631_bib63","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuroscience.2015.08.039","article-title":"The keystone of Alzheimer pathogenesis might be sought in A\u03b2 physiology","volume":"307","author":"Puzzo","year":"2015","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.phrs.2022.106631_bib64","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1399-6576.2012.02769.x","article-title":"Open-heart surgery increases cerebrospinal fluid levels of Alzheimer-associated amyloid \u03b2","volume":"57","author":"Reinsfelt","year":"2013","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.phrs.2022.106631_bib65","first-page":"510","article-title":"Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition","volume":"11","author":"Risacher","year":"2019","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10.1016\/j.phrs.2022.106631_bib66","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3233\/JAD-151113","article-title":"Changes in neuropsychiatric inventory associated with semagacestat treatment of Alzheimer's disease","volume":"54","author":"Rosenberg","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"8","key":"10.1016\/j.phrs.2022.106631_bib67","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","article-title":"Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging","volume":"31","author":"Rowe","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.phrs.2022.106631_bib68","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat. Med."},{"issue":"10284","key":"10.1016\/j.phrs.2022.106631_bib69","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2022.106631_bib70","doi-asserted-by":"crossref","unstructured":"S. Shcherbinin, C.D. Evans, M. Lu, S.W. Andersen, M.J. Pontecorvo, B.A. Willis, I. Gueorguieva, P.M. Hauck, D.A. Brooks, M.A. Mintun, J.R. Sims, Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial, JAMA Neurol., 2022. \u3008https:\/\/doi.org\/10.1001\/jamaneurol.2022.2793\u3009. (Online ahead of print).","DOI":"10.1001\/jamaneurol.2022.2793"},{"issue":"8","key":"10.1016\/j.phrs.2022.106631_bib71","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1073\/pnas.94.8.4109","article-title":"Disaggregation of Alzheimer \u03b2-amyloid by site-directed mAb","volume":"94","author":"Solomon","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.phrs.2022.106631_bib72","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3233\/JAD-2010-100846","article-title":"Is brain amyloid production a cause or a result of dementia of the Alzheimer's type?","volume":"22","author":"Struble","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2022.106631_bib73","doi-asserted-by":"crossref","DOI":"10.3233\/JAD-220808","article-title":"High soluble amyloid-\u03b242 predicts normal cognition in amyloid-positive individuals with Alzheimer's disease-causing mutations","author":"Sturchio","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2022.106631_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100988","article-title":"High cerebrospinal amyloid-\u03b2 42 is associated with normal cognition in individuals with brain amyloidosis","volume":"38","author":"Sturchio","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"12","key":"10.1016\/j.phrs.2022.106631_bib75","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1093\/brain\/awaa332","article-title":"BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain","volume":"143","author":"Sur","year":"2020","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.phrs.2022.106631_bib76","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.phrs.2022.106631_bib77","doi-asserted-by":"crossref","unstructured":"The Lancet, Lecanemab for Alzheimer's disease: tempering hype and hope, Lancet, vol. 400(no. 10367), 2022, 1899.","DOI":"10.1016\/S0140-6736(22)02480-1"},{"key":"10.1016\/j.phrs.2022.106631_bib78","article-title":"Roche Alzheimer\u2019s antibody fails to slow cognitive decline in major test","author":"Travis","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.phrs.2022.106631_bib79","article-title":"Lecanemab in early Alzheimer's disease","author":"van Dyck","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2022.106631_bib80","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.22248","article-title":"Longitudinal assessment of A\u03b2 and cognition in aging and Alzheimer disease","volume":"69","author":"Villemagne","year":"2011","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.phrs.2022.106631_bib81","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.phrs.2022.106631_bib82","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1474-4422(13)70194-7","article-title":"Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study","volume":"12","author":"Vos","year":"2013","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106631_bib83","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s43441-022-00390-4","article-title":"Application of meta-analysis to evaluate relationships among ARIA-E rate, amyloid reduction rate, and clinical cognitive response in amyloid therapeutic clinical trials for early Alzheimer's disease","volume":"56","author":"Wang","year":"2022","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.phrs.2022.106631_bib84","first-page":"652","article-title":"Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia","volume":"4","author":"Willis","year":"2018","journal-title":"Alzheimers Dement."},{"issue":"4","key":"10.1016\/j.phrs.2022.106631_bib85","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00109-006-0143-4","article-title":"Multifunctional antimicrobial peptides: therapeutic targets in several human diseases","volume":"85","author":"Zaiou","year":"2007","journal-title":"J. Mol. Med."},{"issue":"3","key":"10.1016\/j.phrs.2022.106631_bib86","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/cns.12667","article-title":"Chronic sleep restriction induces cognitive deficits and cortical beta-amyloid deposition in mice via BACE1-antisense activation","volume":"23","author":"Zhao","year":"2017","journal-title":"CNS Neurosci. Ther."},{"issue":"667","key":"10.1016\/j.phrs.2022.106631_bib87","doi-asserted-by":"crossref","first-page":"eabn9380","DOI":"10.1126\/scitranslmed.abn9380","article-title":"Synaptogenic effect of APP-Swedish mutation in familial Alzheimer's disease","volume":"14","author":"Zhou","year":"2022","journal-title":"Sci. Transl. Med."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822005771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822005771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:47:15Z","timestamp":1760914035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822005771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":87,"alternative-id":["S1043661822005771"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106631","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of monomeric amyloid-\u03b2 in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106631","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106631"}}